Stephanie H Read1,2,3, Laura C Rosella4,5,6, Howard Berger7, Denice S Feig4,8,9,10, Karen Fleming11, Padma Kaul12,13, Joel G Ray4,6,8,14, Baiju R Shah4,7,8,15, Lorraine L Lipscombe16,4,8,9. 1. Women's College Research Institute, Women's College Hospital, 76 Grenville Street, Toronto, Ontario, M5S 1B2, Canada. Steph.Read@hotmail.com. 2. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. Steph.Read@hotmail.com. 3. Evidence and Access, Certara, London, UK. Steph.Read@hotmail.com. 4. Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. 5. Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. 6. Public Health Ontario, Toronto, Ontario, Canada. 7. Division of Maternal-Fetal Medicine, St. Michael's Hospital, Toronto, Ontario, Canada. 8. Department of Medicine, University of Toronto, Toronto, Ontario, Canada. 9. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. 10. Sinai Health System, Toronto, Ontario, Canada. 11. Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 12. Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada. 13. Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. 14. Department of Obstetrics and Gynaecology, St. Michael's Hospital, Toronto, Ontario, Canada. 15. Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. 16. Women's College Research Institute, Women's College Hospital, 76 Grenville Street, Toronto, Ontario, M5S 1B2, Canada.
Abstract
BACKGROUND: Pregnancy offers a unique opportunity to identify women at higher future risk of type 2 diabetes mellitus (DM). In pregnancy, a woman has greater engagement with the healthcare system, and certain conditions are more apt to manifest, such as gestational DM (GDM) that are important markers for future DM risk. This study protocol describes the development and validation of a risk prediction model (RPM) for estimating a woman's 5-year risk of developing type 2 DM after pregnancy. METHODS: Data will be obtained from existing Ontario population-based administrative datasets. The derivation cohort will consist of all women who gave birth in Ontario, Canada between April 2006 and March 2014. Pre-specified predictors will include socio-demographic factors (age at delivery, ethnicity), maternal clinical factors (e.g., body mass index), pregnancy-related events (gestational DM, hypertensive disorders of pregnancy), and newborn factors (birthweight percentile). Incident type 2 DM will be identified by linkage to the Ontario Diabetes Database. Weibull accelerated failure time models will be developed to predict 5-year risk of type 2 DM. Measures of predictive accuracy (Nagelkerke's R2), discrimination (C-statistics), and calibration plots will be generated. Internal validation will be conducted using a bootstrapping approach in 500 samples with replacement, and an optimism-corrected C-statistic will be calculated. External validation of the RPM will be conducted by applying the model in a large population-based pregnancy cohort in Alberta, and estimating the above measures of model performance. The model will be re-calibrated by adjusting baseline hazards and coefficients where appropriate. DISCUSSION: The derived RPM may help identify women at high risk of developing DM in a 5-year period after pregnancy, thus facilitate lifestyle changes for women at higher risk, as well as more frequent screening for type 2 DM after pregnancy.
BACKGROUND: Pregnancy offers a unique opportunity to identify women at higher future risk of type 2 diabetes mellitus (DM). In pregnancy, a woman has greater engagement with the healthcare system, and certain conditions are more apt to manifest, such as gestational DM (GDM) that are important markers for future DM risk. This study protocol describes the development and validation of a risk prediction model (RPM) for estimating a woman's 5-year risk of developing type 2 DM after pregnancy. METHODS: Data will be obtained from existing Ontario population-based administrative datasets. The derivation cohort will consist of all women who gave birth in Ontario, Canada between April 2006 and March 2014. Pre-specified predictors will include socio-demographic factors (age at delivery, ethnicity), maternal clinical factors (e.g., body mass index), pregnancy-related events (gestational DM, hypertensive disorders of pregnancy), and newborn factors (birthweight percentile). Incident type 2 DM will be identified by linkage to the Ontario Diabetes Database. Weibull accelerated failure time models will be developed to predict 5-year risk of type 2 DM. Measures of predictive accuracy (Nagelkerke's R2), discrimination (C-statistics), and calibration plots will be generated. Internal validation will be conducted using a bootstrapping approach in 500 samples with replacement, and an optimism-corrected C-statistic will be calculated. External validation of the RPM will be conducted by applying the model in a large population-based pregnancy cohort in Alberta, and estimating the above measures of model performance. The model will be re-calibrated by adjusting baseline hazards and coefficients where appropriate. DISCUSSION: The derived RPM may help identify women at high risk of developing DM in a 5-year period after pregnancy, thus facilitate lifestyle changes for women at higher risk, as well as more frequent screening for type 2 DM after pregnancy.
Entities:
Keywords:
Prediction model; Pregnancy; Prognosis; Risk; Study protocol; Type 2 diabetes mellitus
Authors: Matthias B Schulze; Kurt Hoffmann; Heiner Boeing; Jakob Linseisen; Sabine Rohrmann; Matthias Möhlig; Andreas F H Pfeiffer; Joachim Spranger; Claus Thamer; Hans-Ulrich Häring; Andreas Fritsche; Hans-Georg Joost Journal: Diabetes Care Date: 2007-03 Impact factor: 19.112
Authors: Abdulghani H Al-Saeed; Maria I Constantino; Lynda Molyneaux; Mario D'Souza; Franziska Limacher-Gisler; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2016-03-22 Impact factor: 19.112
Authors: Laura C Rosella; Douglas G Manuel; Charles Burchill; Thérèse A Stukel Journal: J Epidemiol Community Health Date: 2010-06-01 Impact factor: 3.710